ARCH VENTURE MANAGEMENT LLC
Q3 2026 Form 13-F
CHICAGO, ILLINOIS
CIK 0001274403
· CRD 158196
· Exempt reporting adviser
$1.6B Reported Value Total
ARCH VENTURE PARTNERS reports under management (AUM).
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Exempt Reporting Adviser
ARCHVENTURE.COM
Source: Form ADV filed 2026-03-30
Reported value
$1.6B
Quarter over quarter
-8.7%
Holdings
17
Top-10 concentration
86.6%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Mark Mcdonnell
Managing Director, CFO and CAO
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $1.6B |
| Positions | 17 |
| Change in reported value | +46.6% |
| New positions | 7 |
| Exited positions | 2 |
| Position turnover | 47.4% |
| Top-10 concentration | 86.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
17 | $1.6B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
12 | $1.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
10 | $677.1M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
9 | $651.7M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
9 | $492.4M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
11 | $299.1M |
|
Q1 2025 13F
Filed May 15, 2025
|
9 | $206.2M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
9 | $230.2M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
9 | $260.6M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
9 | $266.0M |
|
Q1 2024 13F
Filed May 15, 2024
|
8 | $80.3M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
7 | $163.5M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
7 | $154.0M |
|
Q2 2023 13F
Filed Aug 9, 2023
|
6 | $162.0M |
|
Q1 2023 13F
Filed May 15, 2023
|
8 | $207.2M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
8 | $390.4M |
|
Q3 2022 13F
Filed Nov 10, 2022
|
10 | $771.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
10 | $820.6M |
|
Q1 2022 13F
Filed May 13, 2022
|
8 | $699.8M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
9 | $945.3M |
8 earlier quarters on file — choose one from the quarter menu above.
Top 17 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | KARD KARDIGAN INC | $221.9M | 13.75% |
| 2 | PBLS PARABILIS MEDICINES INC | $207.1M | 12.83% |
| 3 | VIR VIR BIOTECHNOLOGY INC | $141.9M | 8.8% |
| 4 | SANA SANA BIOTECHNOLOGY INC | $133.7M | 8.29% |
| 5 | SPTX SEAPORT THERAPEUTICS INC | $127.0M | 7.87% |
| 6 | RAPP RAPPORT THERAPEUTICS INC | $125.3M | 7.77% |
| 7 | SRRK SCHOLAR ROCK HLDG CORP | $113.3M | 7.03% |
| 8 | MAZE MAZE THERAPEUTICS INC | $112.0M | 6.94% |
| 9 | BEAM BEAM THERAPEUTICS INC | $111.0M | 6.88% |
| 10 | ERAS ERASCA INC | $104.0M | 6.44% |
| 11 | MASS 908 DEVICES INC | $70.6M | 4.38% |
| 12 | PRME PRIME MEDICINE INC | $56.5M | 3.5% |
| 13 | LYEL LYELL IMMUNOPHARMA INC | $31.8M | 1.97% |
| 14 | GENB GENERATE BIOMEDICINES INC | $29.2M | 1.81% |
| 15 | NMRA NEUMORA THERAPEUTICS INC. | $20.2M | 1.25% |
| 16 | BOLD BOUNDLESS BIO INC | $6.8M | 0.42% |
| 17 | GOSS GOSSAMER BIO INC | $1.2M | 0.07% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.